Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Perez-Lougee, Giselle Katiria

Massachusetts General Hospital
United States

Thriving Beyond Treatment: A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship 1R37CA303094-01 Marjorie Perloff, M.D.
Perez-Lougee, Giselle Katiria

Massachusetts General Hospital
United States

Thriving Beyond Treatment: A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship 1R37CA303094-01 Marjorie Perloff, M.D.
Perkins, Susan M

Indiana University Indianapolis
United States

Evaluation of the Communication Plan Early through End-of-Life (COMPLETE) Intervention 5R01CA235632-06 Brennan Streck, Ph.D., RN, M.P.H.
Perkins, Susan M

Indiana University Indianapolis
United States

Evaluation of the Communication Plan Early through End-of-Life (COMPLETE) Intervention 5R01CA235632-06 Brennan Streck, Ph.D., RN, M.P.H.
Permuth, Jennifer B

H. Lee Moffitt Cancer Ctr & Res Inst
United States

Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology 5R37CA229810-07 Matthew Young, Ph.D.
Peters, Jeffrey M

Pennsylvania State University, The
United States

Unique targeting of PPARβ/δ regulation for cancer prevention and therapy 5R01CA239256-05 Marjorie Perloff, M.D.
Pfleger, Cathie M

Icahn School Of Medicine At Mount Sinai
United States

A Drosophila model for Aromatase Inhibitor-induced Musculoskeletal Pain 1R21CA303409-01 Rachel Altshuler, Ph.D.
Pfleger, Cathie M

Icahn School Of Medicine At Mount Sinai
United States

A Drosophila model for Aromatase Inhibitor-induced Musculoskeletal Pain 1R21CA303409-01 Rachel Altshuler, Ph.D.
Phillips, Nicholas S

St. Jude Children'S Research Hospital
United States

Cardiopulmonary function and cerebral blood flow in Hodgkin Lymphoma survivors 5R21CA280230-02 Eileen Dimond, R.N., M.S.
Phillips, Nicholas S

St. Jude Children'S Research Hospital
United States

Cardiopulmonary function and cerebral blood flow in Hodgkin Lymphoma survivors 5R21CA280230-02 Eileen Dimond, R.N., M.S.
Pinder, Leeya F

University Of Cincinnati
United States

RepurPosed AntiretrOviraL ThErapieS to EliminAte Cervical Cancer (POLESA Trial) 3R37CA284033-03S1 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Pistilli, Emidio Edward

West Virginia University
United States

Targeting Muscle Fatigability During Cachexia 5R01AR079445-04 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Pistilli, Emidio Edward

West Virginia University
United States

Targeting Muscle Fatigability During Cachexia 5R01AR079445-04 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Pitteri, Sharon

Stanford University
United States

Glycosylation and Immune Evasion in Urologic Tumors 5U01CA226051-05
Plas, Ellen Van Der

Arkansas Children'S Hospital Res Inst
United States

Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia 5R37CA266135-04 Asad Umar, D.V.M., Ph.D.